Start Date
March 6, 2011
Primary Completion Date
May 4, 2011
Study Completion Date
May 4, 2011
SPD489
1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
Placebo
1 capsule per day for one week of the double-blind crossover phase
Florida Clinical Research Center, LLC, Bradenton
Vince and Associates Clinical Research, Inc., Overland Park
Clinical Study Centers, LLC, Little Rock
Bayou City Research, Ltd., Houston
John M. Turnbow, MD, PA, Lubbock
Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas
Lead Sponsor
Shire
INDUSTRY